US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% NVDA $233.95 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% JNJ $256.03 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Articles published by Lisata Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Present at the 2025 BIO International Convention
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Announces Research License with Catalent
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Present at the Investival Showcase USA
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
< Previous 1 2 3 Next >